FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic more...
Being a client-centric organization, we are engaged in offering a distinct array of Fulvenat Injection. Application: Used to treat some types of metastatic breast cancer that require estrogen. Features: Precise composition Hygienically processed Long shelf life more...